• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Intelligent Bio Solutions Inc.

    5/30/25 5:26:11 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care
    Get the next $INBS alert in real time by email
    S-8 1 forms-8.htm S-8

     

    As filed with the Securities and Exchange Commission on May 30, 2025

     

    Registration No. 333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    Registration Statement

    under

    The Securities Act of 1933

     

    INTELLIGENT BIO SOLUTIONS INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   82-1512711

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. employer

    identification no.)

     

    135 West, 41st Street, 5th Floor

    New York, NY 10036

    (Address of principal executive offices, including zip code)

     

    Intelligent Bio Solutions Inc. 2019 Long Term Incentive Plan

    (Full title of the plan)

     

    Harry Simeonidis

    President and Chief Executive Officer

    135 West, 41st Street, 5th Floor

    New York, NY 10036

    (Name and address of agent for service)

     

    (646) 828-8258

    (Telephone number, including area code, of agent for service)

     

    With a copy to:

     

    Ralph V. De Martino, Esq.

    Johnathan C. Duncan, Esq.

    ArentFox Schiff LLP

    901 K Street NW, Suite 700

    Washington, DC 20001

    Tel: (202) 724-6848

    Fax: (202) 778-6460

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐   Accelerated filer ☐
         
    Non-accelerated filer ☒   Smaller reporting company ☒
         
        Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    Intelligent Bio Solutions Inc. (the “Registrant”) has prepared this registration statement on Form S-8 (the “Registration Statement”) to register an additional 1,166,666 shares of the Registrant’s common stock, par value $0.01 per share (“Common Stock”), for issuance under the Intelligent Bio Solutions Inc. 2019 Long Term Incentive Plan (the “2019 Plan”).

     

    On February 8, 2023, the stockholders of the Registrant approved an amendment to the 2019 Plan to increase the number of shares of Common Stock authorized for issuance thereunder from 2,084 shares to 6,250 shares; and on May 8, 2023, the stockholders of the Registrant approved a second amendment to the 2019 Plan to increase the number of shares of Common Stock authorized for issuance thereunder from 6,250 shares to 10,417 shares.

     

    On December 13, 2023, the stockholders of the Registrant approved a third amendment to the 2019 Plan to increase the number of shares of Common Stock authorized for issuance thereunder from 10,417 shares to 133,334 shares.

     

    On May 8, 2025, the stockholders of the Registrant approved a fourth amendment to the 2019 Plan to increase the number of shares of Common Stock authorized for issuance thereunder from 133,334 shares to 1,300,000 shares. Accordingly, this Registration Statement registers the additional 1,166,666 shares of the Registrant’s Common Stock added to the 2019 Plan.

     

    Pursuant to General Instruction E to Form S-8, the contents of the earlier registration statements on Form S-8 concerning the 2019 Plan filed with the Securities and Exchange Commission (the “Commission”) on August 5, 2022 (Registration File No. 333-266571), and on May 31, 2023 (Registration File No. 333-272305), and on January 12, 2024 (Registration File No. 333-276499) (collectively, the “Prior Registration Statements”) are incorporated herein by reference, except to the extent supplemented or amended or superseded by the information set forth herein.

     

    This Registration Statement relates to securities of the same class as that to which the Prior Registration Statements relate.

     

    All share amounts in this Registration Statement have been adjusted to reflect the 1-for-20 reverse stock split that was effected on February 9, 2023 and the 1-for-12 reverse stock split effected on January 26, 2024.

     

     

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The Registrant hereby incorporates by reference in this Registration Statement the following documents and information previously filed with the Securities and Exchange Commission, other than any portions of the respective filing that were furnished, pursuant to Item 2.02 or Item 7.01 of Current Reports on Form 8-K (including exhibits related thereto) or other applicable SEC rules, rather than filed:

     

    ● the Registrant’s Annual Report on Form 10-K for the year ended June 30, 2024 (filed on September 18, 2024), as amended on Form 10-K/A (filed on February 13, 2025);
       
    ● the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (filed on November 7, 2024);
       
    ● the Registrant’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2024 (filed on February 13, 2025);
       
    ● the Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 (filed on May 13, 2025);
       
    ● the Registrant’s Current Reports on Form 8-K and any amendments on Form 8-K/A filed on July 24, 2024; September 18, 2024; September 27, 2024; November 13, 2024; January 6, 2025; February 21, 2025; March 14, 2025; and May 13, 2025;
       
    ● the Registrant’s Definitive Proxy Statement on Schedule 14A filed on April 1, 2025; and
       
    ● the description of the Registrant’s Common Stock contained in the Registrant’s registration statement Form 8-A filed with the SEC on December 22, 2020, and any other amendment or report filed for the purpose of updating such description, including any exhibits to our Annual Report on Form 10-K.

     

    All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, other than current reports, or portions thereof, furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed on such form that are related to such items, subsequent to the date hereof and prior to the filing of a post-effective amendment that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall also be deemed to be incorporated by reference herein and to be a part hereof from the dates of filing of such documents.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

     

     

     

    Item 8. Exhibits.

     

    Exhibit No.   Description
         
    4.1   Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.4 to the Company’s Amended Registration Statement on Form S-1/A (File No. 333-232557) filed with the Commission on December 21, 2020).
         
    4.2   Certificate of Amendment to the Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Commission on October 27, 2022).
         
    4.3   Certificate of Amendment to Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Commission on February 9, 2023).
         
    4.4   Amended and Restated Bylaws of Intelligent Bio Solutions Inc., as amended as of October 26, 2022 (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed with the Commission on October 27, 2022).
         
    4.5   Certificate of Designation of Series B Preferred Stock (incorporated by reference to Exhibit 3.3 to the Company’s Amended Registration Statement on Form S-1/A (File No. 333-232557) filed with the Commission on October 20, 2020).
         
    4.6   Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Commission on October 11, 2022).
         
    4.7   Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Commission on December 22, 2022).
         
    4.8   Certificate of Elimination of Series B Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Commission on July 26, 2023).
         
    4.9   Certificate of Elimination of Series D Convertible Preferred Stock (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed with the Commission on July 26, 2023).
         
    4.10   Certificate of Designation of Preferences, Rights and Limitations of the Series E Convertible Preferred Stock, filed with the Delaware Secretary of State on October 3, 2023 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Commission on October 4, 2023).
         
    4.11   Certificate of Amendment to Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Commission on January 26, 2024).
         
    5.1*   Opinion of ArentFox Schiff LLP
         
    23.1*   Consent of UHY LLP
         
    23.2*   Consent of ArentFox Schiff LLP (contained in the Opinion filed as Exhibit 5.1).
         
    24.1*   Powers of Attorney (contained on the signature pages hereto).
         
    99.1   Intelligent Bio Solutions Inc. 2019 Long Term Incentive Plan (as amended May 8, 2025) (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on May 13, 2025).
         
    99.2*   Form of Director Stock Award Agreement
         
    99.3*   Form of US Employee Stock Award Agreement
         
    99.4*   Form of UK/AU Employee Stock Award Agreement
         
    107*   Filing Fee Table

     

    * Filed herewith.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Sydney, Australia, on May 30, 2025.

     

      INTELLIGENT BIO SOLUTIONS INC.
      (Registrant)
         
      By: /s/ Harry Simeonidis
        Harry Simeonidis
        President and Chief Executive Officer

     

    POWER OF ATTORNEY

     

    Each person whose signature appears below appoints Steven Boyages and Spiro Sakiris or either one of them, as such person’s true and lawful attorneys to execute in the name of each such person, and to file, any pre-effective or post-effective amendments to this Registration Statement that any of such attorneys shall deem necessary or advisable to enable the Registrant to comply with the Securities Act of 1933, as amended, and any rules, regulations and requirements of the Securities and Exchange Commission with respect thereto, in connection with this Registration Statement, which amendments may make such changes in such Registration Statement as any of the above-named attorneys deems appropriate, and to comply with the undertakings of the Registrant made in connection with this Registration Statement; and each of the undersigned hereby ratifies all that any of said attorneys shall do or cause to be done by virtue thereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Harry Simeonidis   Chief Executive Officer and President   May 30, 2025
    Harry Simeonidis   (Principal Executive Officer)    
             
    /s/ Spiro Sakiris   Chief Financial Officer   May 30, 2025
    Spiro Sakiris   (Principal Financial Officer and Principal Accounting Officer)    
             
    /s/ Steven Boyages   Chairman of the Board   May 30, 2025
    Steven Boyages MB BS, PhD        
             
    /s/ Jonathan Hurd   Director   May 30, 2025
    Jonathan Hurd        
             
    /s/ Jason Isenberg   Director   May 30, 2025
    Jason Isenberg        
             
    /s/ Nicola Fraser   Director   May 30, 2025
    Nicola Fraser        

     

     

     

     

    Get the next $INBS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INBS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $INBS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Intelligent Bio Solutions to Showcase Fingerprint Drug Testing at RISE25 Conference from May 28-31, Supporting Innovation in U.S. Forensic Drug Testing

      INBS to participate with U.S. distribution partner SMARTOX at RISE25, the leading U.S. conference on addiction, mental health, and justice innovation which draws over 7,000 attendees annually With over 450 active accounts across 24 countries, INBS continues to meet growing global demand for reliable, on-site drug testing solutions across the workplace, treatment, and justice sectors NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its participation at the All Rise Conference, RISE25, in Kissimmee, Florida from May 28

      5/22/25 8:30:00 AM ET
      $INBS
      Medical/Dental Instruments
      Health Care
    • Intelligent Bio Solutions Showcases Rapid, Non-Invasive Drug Testing Capabilities in Remote Queensland Workforce Deployment

      NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of a high-volume workforce drug test for Barcaldine Regional Council in remote Queensland, Australia, (the "Council") using its Intelligent Fingerprinting Drug Screening System (the "System"). This initiative supports the Company's expansion into regional and remote workforce testing markets. In less than 90 minutes, more than 160 employees, representing 100% of the workforce, were tested and cleared as fit for duty before the start of the work

      5/19/25 8:30:00 AM ET
      $INBS
      Medical/Dental Instruments
      Health Care
    • Intelligent Bio Solutions Accelerates Global Adoption of Fingerprint Drug Testing

      NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced recent growth highlights across its global operations, driven by new account acquisitions, expansion into new testing areas and sectors, and continued penetration into safety-critical industries. The Company's total number of active accounts has surpassed 450, with 35 new accounts added in fiscal Q3 alone. INBS' Intelligent Fingerprinting Drug Screening System, which detects recent drug use in under ten minutes through fingerprint sweat analysis, continues to gain tra

      5/15/25 9:00:00 AM ET
      $INBS
      Medical/Dental Instruments
      Health Care

    $INBS
    SEC Filings

    See more
    • SEC Form S-8 filed by Intelligent Bio Solutions Inc.

      S-8 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

      5/30/25 5:26:11 PM ET
      $INBS
      Medical/Dental Instruments
      Health Care
    • Intelligent Bio Solutions Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

      5/16/25 8:00:18 AM ET
      $INBS
      Medical/Dental Instruments
      Health Care
    • Intelligent Bio Solutions Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

      5/13/25 5:15:23 PM ET
      $INBS
      Medical/Dental Instruments
      Health Care

    $INBS
    Financials

    Live finance-specific insights

    See more
    • Intelligent Bio Solutions Announces Fiscal Q3 2025 Financial Results and Key Operational Achievements

      20% sequential quarterly revenue growth and 91% year-over-year quarterly gross profit growth Continued momentum from recurring higher-margin cartridge sales now reaching 58% of total sales for the nine months ended March 31, 2025  35 new accounts and international growth during Q3 bring total active accounts to over 450 NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for the fiscal third quarter and nine months ended March 31, 2025, and provided a business update.   The Company delivered a st

      5/13/25 8:30:00 AM ET
      $INBS
      Medical/Dental Instruments
      Health Care
    • Intelligent Bio Solutions Announces Fiscal Q2 2025 Financial Results and Key Operational Achievements

      Gross profit increase of 32.6% and 11-point gross profit margin increase driven by higher-margin cartridge sales Submitted FDA 510(k) and remain on track for planned expansion into multi-billion dollar U.S. market in 2025 Added strategic partnerships, increasing visibility across the Asia-Pacific Region and the U.S. Secured 19 accounts during quarter, adding to 400+ active customer accounts in 19 countries NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for the fiscal second quarter and six

      2/13/25 8:30:00 AM ET
      $INBS
      Medical/Dental Instruments
      Health Care
    • Intelligent Bio Solutions Inc. Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results and Operational Highlights

      - Fourth-quarter revenue of $0.73 million, up 64% year-over-year – - Full-year revenue of $3.11 million, up 148% year-over-year – - As of June 30, 2024, the Company had $6.30 million in cash - NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, announced its financial results for the fiscal fourth quarter and full-year ended June 30, 2024, and provided a business update. Fiscal fourth quarter revenue totalled $0.73 million, an increase of 64% compared to the same period the prior year, and full-year revenue totalled $3.11 million,

      9/19/24 8:30:00 AM ET
      $INBS
      Medical/Dental Instruments
      Health Care

    $INBS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $INBS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form SC 13G/A filed by Intelligent Bio Solutions Inc.

      SC 13G/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

      11/14/24 7:16:17 PM ET
      $INBS
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Intelligent Bio Solutions Inc.

      SC 13G - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

      11/14/24 4:31:30 PM ET
      $INBS
      Medical/Dental Instruments
      Health Care
    • Amendment: Chief Financial Officer Sakiris Spiro Kevin was granted 34,500 shares, increasing direct ownership by 10,952% to 34,815 units (SEC Form 4)

      4/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)

      3/31/25 4:15:27 PM ET
      $INBS
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Simeonidis Harry was granted 40,000 shares, increasing direct ownership by 9,804% to 40,408 units (SEC Form 4)

      4 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)

      9/27/24 5:00:16 PM ET
      $INBS
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Sakiris Spiro Kevin was granted 34,500 shares, increasing direct ownership by 10,952% to 34,815 units (SEC Form 4)

      4 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)

      9/27/24 5:00:15 PM ET
      $INBS
      Medical/Dental Instruments
      Health Care